- Home
- CEV vs PMVP Comparison
CEV vs PMVP Comparison
Compare CEV & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | PMVP |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 79.8M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CEV | PMVP |
|---|---|---|
| Price | $10.43 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 7.6K | ★ 824.8K |
| Earning Date | 01-01-0001 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.31 | $0.82 |
| 52 Week High | $10.78 | $1.88 |
Technical Indicators
Market Signals| Indicator | CEV | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 56.17 |
| Support Level | $10.33 | $1.32 |
| Resistance Level | $10.62 | $1.64 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 7.28 | 8.54 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.